Search
for
Sort by
Research 391–420 of 1000+
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Application of Topical Immunotherapy in the Treatment of Alopecia Areata: A Review and Update
- Characterization of Clinical Features of Hospitalized Patients Due to the SARS-CoV-2 Infection in the Absence of Comorbidities Regarding the Sex: An Epidemiological Study of the First Year of the Pandemic in Brazil
- Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
- Molecular Mechanisms Lead to Sex-Specific COVID-19 Prognosis and Targeted Therapies
- CD44 signaling in skin wound healing and regeneration
- Regulatory T cell dysfunction and immunotherapeutic breakthroughs in type 1 diabetes
- Wounds and the Microbiota: The Healing Interplay Between Host and Microbial Communities
- Comorbid Bronchial Asthma, Atopic Dermatitis and Hashimoto's Thyroiditis Are Risk Factors for Early‐Onset, Severe and Prolonged Alopecia Areata
- Off-label dermatologic uses of IL-23 inhibitors
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Human Regulatory T Cells: Understanding the Role of Tregs in Select Autoimmune Skin Diseases and Post-Transplant Nonmelanoma Skin Cancers
- Astilbin Activates the Reactive Oxidative Species/PPARγ Pathway to Suppress Effector CD4+ T Cell Activities via Direct Binding With Cytochrome P450 1B1
- Potential Treatment of Steroid‐Resistant Alopecia Areata Using Allogeneic Exosomes Derived From Adipose Tissue Mesenchymal Stromal Cells: A Case Report
- Advancements in Bioactive Compounds and Therapeutic Agents for Alopecia: Trends and Future Perspectives
- Decoding Gut Microbiome Dysbiosis as a Non-Invasive Diagnostic Biomarker for Alopecia Areata
- Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies
- An Updated in the Management of Alopecia Areata
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions
- The Role of the Microbiome in the Resolution of Infection-Induced Inflammation
- Microneedle Arrays Combined with Nanomedicine Approaches for Transdermal Delivery of Therapeutics
- Efficacy of probiotics in hair growth and dandruff control: A systematic review and meta-analysis
- DataSheet1_Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention.PDF
- Platelet-Rich Plasma: New Performance Understandings and Therapeutic Considerations in 2020
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
- Intestinal Intraepithelial Lymphocytes: Sentinels of the Mucosal Barrier
- Inflammatory priming enhances mesenchymal stromal cell secretome potential as a clinical product for regenerative medicine approaches through secreted factors and EV-miRNAs: the example of joint disease
- The Role of Exosomes Derived From Mesenchymal Stromal Cells in Dermatology
- Keratins as an Inflammation Trigger Point in Epidermolysis Bullosa Simplex